---
title: "Niagen Bioscience posts investor presentation focused on NAD+ science and healthy-aging products"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294877506.md"
description: "Niagen Bioscience released an investor presentation highlighting its strategy centered on NAD+ science and healthy-aging products. Key initiatives include Tru Niagen, the leading U.S. NAD+ supplement, and Niagen Plus targeting the $500 million IV/injection market with improved safety profiles. The company reports distribution in over 1,700 clinics and is expanding its pipeline into Nanocloud skincare and drug development for rare genetic diseases."
datetime: "2026-08-04T21:50:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294877506.md)
  - [en](https://longbridge.com/en/news/294877506.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294877506.md)
generator: "portal-rs"
---

# Niagen Bioscience posts investor presentation focused on NAD+ science and healthy-aging products

-   Niagen Bioscience outlined a strategy centered on NAD+ science, led by its patented nicotinamide riboside supplement franchise. \* Tru Niagen positioned as the No. 1 NAD+ healthy aging supplement in the U.S., supported by clinician sharing on FrontrowMD. \* Niagen Plus targeted a NAD+ IV and injections market estimated at about $500 million, citing improved administration time and fewer side effects. \* Niagen IV reported distribution in more than 1,700 clinics nationwide, including large wellness providers. \* Pipeline expanded beyond supplements into Nanocloud skincare and drug development for rare genetic diseases. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NAGE.US](https://longbridge.com/en/quote/NAGE.US.md)

## Related News & Research

- [Is Niagen Bioscience (NAGE) Quietly Recasting Its Brand Around E‑Commerce Scale And Clinical Proof](https://longbridge.com/en/news/295196539.md)
- [Under-eye patches aren’t just skincare anymore. Now, they're a flex.](https://longbridge.com/en/news/296597484.md)
- [09:02 ETYNS Skin Care Advances Physician-Formulated Skincare With PharmD Expertise and Facial Cosmetic Surgery Insight](https://longbridge.com/en/news/296232824.md)
- [07:12 ETPROYA s'associe à Ulta Beauty : élargir l'éventail des soins haut de gamme de ce détaillant dans le courant de l'année](https://longbridge.com/en/news/296480642.md)
- [Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half](https://longbridge.com/en/news/296638124.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**